Company Overview of Labopharm Inc.
Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies worldwide. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of patients with moderate to moderately severe pain; Oleptro, a novel once-daily formulation of trazodone for the treatment of major depressive disorder; and twice-daily formulation combining the analgesics tramadol and acetaminophen for the treatment of pain. The company’s novel and proprietary drug delivery technologies include Intellitab technology for the development of abuse-and misuse-deterrent formulations of drugs; polymeric nano-delivery s...
480 Armand-Frappier Boulevard
Laval, QC H7V 4B4
Founded in 1990
Key Executives for Labopharm Inc.
Chief Executive Officer, President and Director
Senior Vice President of Research & Development
Managing Director of Labopharm Europe Limited
Compensation as of Fiscal Year 2014.
Labopharm Inc. Key Developments
Altus Formulation Signs Agreement With Zogenix for Development of Abuse Deterrent Formulations of Zohydro(TM) ER
Nov 4 13
Altus Formulation Inc. announced that it has entered into a Development and Option Agreement with Zogenix, Inc., to develop abuse deterrent formulations of Zohydro(TM) ER using Altus's proprietary, clinically validated Intellitab drug delivery platform. Altus and Zogenix have initiated development of Intellitab abuse deterrent formulations of Zohydro ER with the entry into the agreement. Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules, an opioid agonist, is the first approved extended-release oral formulation of hydrocodone without acetaminophen, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Zogenix, Inc. Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER with Altus Formulation Inc
Nov 1 13
Zogenix Inc. announced that it has entered into a Development and Option Agreement with Altus Formulation Inc. to develop abuse deterrent formulations of Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules, using Altus's proprietary Intellitab(TM) drug delivery platform. Concurrent with entry into this agreement, Altus and Zogenix have initiated development of alternative abuse deterrent formulations of Zohydro ER. Under the D&O Agreement, Altus has granted Zogenix an option (subject to the terms and conditions of the D&O Agreement) to enter into an exclusive license on mutually agreed terms to develop and commercialize abuse deterrent formulations of Zohydro ER in the United States. In connection with the transaction, Zogenix will pay Altus a technology access fee in the amount of $750,000. Zogenix will fund all development activities, and Altus may earn up to an additional $3.5 million in development and regulatory milestones through submission of a New Drug Application (NDA) under the D&O Agreement. Following exercise of the option, Altus will be eligible to receive additional undisclosed regulatory and sales milestone payments and a royalty based on net sales of the licensed product.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries